Success Metrics

Clinical Success Rate

60.0%

Based on 3 completed trials

Completion Rate

60%(3/5)

Active Trials

1(14%)

Results Posted

133%(4 trials)

Terminated

2(29%)

Phase Distribution

Ph phase_3

29%

Ph phase_4

57%

Ph phase_2

14%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution7 total trials

Phase 2Efficacy & side effects

1(14.3%)

Phase 3Large-scale testing

2(28.6%)

Phase 4Post-market surveillance

4(57.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(3)

Terminated(2)

Other(1)

Detailed Status

Completed3

Terminated2

Active, not recruiting1

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

60.0%

Most Advanced

Phase 4

Trials by Phase

Phase 21 (14.3%)

Phase 32 (28.6%)

Phase 44 (57.1%)

Trials by Status

completed343%

active_not_recruiting114%

terminated229%

unknown114%

Recent Activity

1 active trials

Showing 5 of 7

active_not_recruitingphase_4

ASCEND: A Study of Cardiovascular Events iN Diabetes

NCT00135226

completedphase_4

XIENCE V® USA Dual Antiplatelet Therapy (DAPT) Cohort

NCT01106534

terminatedphase_3

Effect of Platelet Inhibition and / or Lipid Lowering in Non-ACS-patients With Positive Troponin

NCT03820466

terminatedphase_3

Study Comparing Ticagrelor With Aspirin for Prevention of Vascular Events in Patients Undergoing CABG

NCT01755520

completedphase_2

Anti-platelet Therapy in the Prevention of Cardiovascular Disease in Patients With COPD (APPLE-COPD: ICON 2)

NCT03487406

View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials

NCT00135226Phase 4

ASCEND: A Study of Cardiovascular Events iN Diabetes

Active Not Recruiting

NCT01106534Phase 4

XIENCE V® USA Dual Antiplatelet Therapy (DAPT) Cohort

Completed

NCT03820466Phase 3

Effect of Platelet Inhibition and / or Lipid Lowering in Non-ACS-patients With Positive Troponin

Terminated

NCT01755520Phase 3

Study Comparing Ticagrelor With Aspirin for Prevention of Vascular Events in Patients Undergoing CABG

Terminated

NCT03487406Phase 2

Anti-platelet Therapy in the Prevention of Cardiovascular Disease in Patients With COPD (APPLE-COPD: ICON 2)

Completed

NCT00977938Phase 4

The Dual Antiplatelet Therapy Study (DAPT Study)

Completed

NCT00954707Phase 4

CYPRESS - CYPHER for Evaluating Sustained Safety

Unknown

All 7 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 7